Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sunhawk Vision Biotech, Inc (7759) Fair Value & Analysis

Healthcare · TW · Market cap 2.1B TWD

Price29.95 TWD
Fair Value20.12 TWD
Upside-32.8%
Quality87/100
Evidence: Low Range 15.09 TWD – 25.15 TWD

Fair value as of: Jun 24, 2026

Analysis

Sunhawk Vision Biotech, Inc (7759) currently trades at 29.95 TWD, while our model-based Fair Value estimate is 20.12 TWD — implying the stock looks roughly 32.8% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Sunhawk Vision Biotech, Inc. operates as a drug development company that develops microRNA therapeutic eye drops. Its flagship product is SHJ002 eye drops. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Sunhawk Vision Biotech, Inc (7759) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 20.12 TWD versus a price of 29.95 TWD — about −33% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7759?
Our 21-model fair value for Sunhawk Vision Biotech, Inc is 20.12 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 29.95 TWD.
What is the quality score of 7759?
Sunhawk Vision Biotech, Inc has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.